Kopp Family Office LLC Purchases Shares of 34,540 CeriBell, Inc. $CBLL

Kopp Family Office LLC acquired a new position in shares of CeriBell, Inc. (NASDAQ:CBLL) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 34,540 shares of the company’s stock, valued at approximately $672,000. CeriBell accounts for about 0.4% of Kopp Family Office LLC’s holdings, making the stock its 20th largest holding. Kopp Family Office LLC owned approximately 0.09% of CeriBell at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Royce & Associates LP acquired a new stake in CeriBell during the 4th quarter worth about $11,695,000. KCM Capital Inc increased its holdings in shares of CeriBell by 40.0% in the first quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock valued at $25,662,000 after purchasing an additional 400,000 shares during the period. Bank of America Corp DE increased its holdings in shares of CeriBell by 15.3% in the first quarter. Bank of America Corp DE now owns 319,837 shares of the company’s stock valued at $5,863,000 after purchasing an additional 42,340 shares during the period. Sei Investments Co. raised its stake in shares of CeriBell by 2.3% in the first quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock worth $923,000 after purchasing an additional 1,125 shares during the last quarter. Finally, Quantinno Capital Management LP lifted its holdings in shares of CeriBell by 3.0% during the first quarter. Quantinno Capital Management LP now owns 140,347 shares of the company’s stock worth $2,573,000 after purchasing an additional 4,119 shares during the period.

CeriBell News Roundup

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: FDA clearance strengthens the product offering. CeriBell received 510(k) clearance for two AI enhancements to its cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction. The features are designed to help neurologists identify abnormal EEG patterns, reduce signal interference and interpret recordings more efficiently in emergency and intensive-care settings. The upgrades require no installation downtime and could improve the clinical utility and adoption of CeriBell’s point-of-care monitoring system. CeriBell FDA clearance announcement
• Positive Sentiment: Quarterly revenue exceeded expectations. CeriBell reported second-quarter revenue of $28.1 million, above the roughly $27.3 million analyst consensus. The company also issued full-year 2026 revenue guidance of $114 million to $117 million, with the midpoint modestly above consensus expectations of $114 million. CeriBell second-quarter 2026 results
• Neutral Sentiment: Institutional interest is mixed. Recent filings show more institutions added CeriBell shares than reduced positions, including sizable additions by FMR, Adage Capital and Millennium Management. However, other investors also trimmed holdings, so the data does not provide a clear near-term signal.
• Negative Sentiment: The quarterly loss was wider than expected and increased year over year. CeriBell reported a loss of $0.51 per share, compared with analyst estimates ranging from $0.45 to $0.47 and a $0.38 loss in the year-ago quarter. The company continues to post substantial losses, including a negative net margin, which may limit enthusiasm despite revenue growth. CeriBell second-quarter earnings analysis
• Negative Sentiment: Insider selling could weigh on sentiment. Reported insider activity over the past six months included numerous sales and no open-market purchases, including selling by senior executives. While such transactions may reflect personal liquidity needs, the absence of insider buying is a potentially cautious signal for investors.

Insider Buying and Selling at CeriBell

In other news, CTO Raymond Woo sold 1,966 shares of the stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $18.00, for a total transaction of $35,388.00. Following the sale, the chief technology officer directly owned 195,682 shares of the company’s stock, valued at $3,522,276. This represents a 0.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Tpg Gp A, Llc sold 202,368 shares of CeriBell stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $20.12, for a total value of $4,071,644.16. Following the completion of the transaction, the insider owned 3,765,054 shares of the company’s stock, valued at approximately $75,752,886.48. This represents a 5.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 300,685 shares of company stock worth $5,935,326. 17.70% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

CBLL has been the topic of several research reports. Canaccord Genuity Group cut their price target on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. Weiss Ratings cut shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, CeriBell currently has a consensus rating of “Moderate Buy” and an average target price of $22.20.

CeriBell Trading Up 2.6%

CeriBell stock opened at $19.30 on Tuesday. The firm has a market cap of $732.24 million, a PE ratio of -11.84 and a beta of 0.81. CeriBell, Inc. has a 12 month low of $10.85 and a 12 month high of $24.33. The stock’s 50 day simple moving average is $18.55 and its two-hundred day simple moving average is $19.08. The company has a current ratio of 10.44, a quick ratio of 10.01 and a debt-to-equity ratio of 0.14.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.04). CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. The firm had revenue of $28.10 million during the quarter, compared to analyst estimates of $27.28 million. Analysts anticipate that CeriBell, Inc. will post -1.69 earnings per share for the current year.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.